Trane Technologies Recognized by TIME as One of the World's Most Sustainable Companies
'We are honored to be named to TIME's list of the 2025 World's Most Sustainable Companies for the second consecutive year,' said Mauro Atalla, Senior Vice President, Chief Technology and Sustainability Officer, Trane Technologies. 'Our inclusion on this prestigious list underscores our dedication to driving sustainable growth for ourselves and our customers and making a lasting positive impact on our planet.'
Since 2019, Trane Technologies has reduced customer carbon emissions by 237 million metric tons, on track to meet its Gigaton Challenge goal of reducing one gigaton (or one billion metric tons) of customer carbon emissions by 2030. Last year, the company introduced 190 new products, including a major portfolio update featuring refrigerants with lower global warming potential (GWP).
Trane Technologies is widely recognized as a leader in sustainability, integrating sustainable practices into the company's core strategy and throughout its global operations as it progresses toward its 2030 Sustainability Commitments. The company is dedicated to developing industry-leading climate solutions for customers worldwide, including innovative, energy-efficient products and solutions that help customers achieve their sustainability goals while improving their bottom line by reducing energy use, carbon emissions, and operational costs.
The company is also acknowledged for its industry-leading transparency, credibility, and accountability, having recently received several additional recognitions for climate action. Trane Technologies ranked in the top ten of Corporate Knights' inaugural Europe 50 list and was featured on the Financial Times' list of Europe's Climate Leaders for the fifth consecutive year.
# # #
About Trane TechnologiesTrane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. Visit tranetechnologies.com.
This news release includes 'forward-looking statements' within the meaning of securities laws, which are statements that are not historical facts, including statements that relate to our sustainability commitments and the anticipated impact of these commitments. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties, which may cause actual results to differ materially from our current expectations. Factors that could cause such differences can be found in our Form 10-K for the year ended December 31, 2024, as well as our subsequent reports on Form 10-Q and other SEC filings. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect the Company. We assume no obligation to update these forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Villarreal set to break their transfer record
Villarreal set to break their transfer record originally appeared on The Sporting News Villarreal had a pretty good season last year as they finished 5th in La Liga last year and qualified for the Champions League. They started off their league campaign with a comfortable win against Real Oviedo and seem like they're on track for another good season. It seems like Villarreal are also expecting to have a good season as they are reportedly looking to improve their team by making a record signing. Renato Veiga to Villarreal Portuguese centre back Renato Veiga is heading to Villarreal on a seven year deal according to Fabrizio Romano. The club is set to pay Chelsea 29.5 million euros with a 40% sell-on clause that helped entice The Blues to complete the deal. The Portuguese centre back spent last season on loan at Juventus as he had struggled to settle in with Chelsea falling victim to the constant buying and selling of young talents that have become a staple of the new regime. Now, the talented centre back has the chance to settle down and develop and could become one of the best centre backs in the league. Villarreal Ambitions Villarreal fans should be ecstatic with this signing as their club is showing the ambition to build on last season and improve the team. They improve on their centre backs and should be able to make the starting eleven. It's the right move to make when the club is competing in multiple competitions this year. Villarreal will hope to make a significant push in Europe and push to be the best of the rest in La Liga.
Yahoo
43 minutes ago
- Yahoo
China rushes to build out solar, and emissions edge downward
TALATAN, China (AP) — High on the Tibetan plateau, Chinese government officials last month showed off what they say will be the world's largest solar farm when completed — 610 square kilometers (235 square miles), the size of the American city of Chicago. China has been installing solar panels at a blistering pace, far faster than anywhere else in the world, and the investment is starting to pay off. A study released Thursday found that the country's carbon emissions edged down 1% in the first six months of the year compared to a year earlier, extending a trend that began in March 2024. The good news is China's carbon emissions may have peaked well ahead of a government target of doing so before 2030. But China, the world's biggest emitter of greenhouse gases, will need to bring them down much more sharply to play its part in slowing global climate change. For China to reach its declared goal of carbon neutrality by 2060, emissions would need to fall 3% on average over the next 35 years, said Lauri Myllyvirta, the Finland-based author of the study and lead analyst at the Centre for Research on Energy and Clean Air. 'China needs to get to that 3% territory as soon as possible,' he said. China's emissions have fallen even as it uses more electricity China's emissions have fallen before during economic slowdowns. What's different this time is electricity demand is growing — up 3.7% in the first half of this year — but the increase in power from solar, wind and nuclear has easily outpaced that, according to Myllyvirta, who analyzes the most recent data in a study published on the U.K.-based Carbon Brief website. 'We're talking really for the first time about a structural declining trend in China's emissions,' he said. China installed 212 gigawatts of solar capacity in the first six months of the year, more than America's entire capacity of 178 gigawatts as of the end of 2024, the study said. Electricity from solar has overtaken hydropower in China and is poised to surpass wind this year to become the country's largest source of clean energy. Some 51 gigawatts of wind power was added from January to June. Li Shuo, the director of the China Climate Hub at the Asia Society Policy Institute in Washington, described the plateauing of China's carbon emissions as a turning point in the effort to combat climate change. 'This is a moment of global significance, offering a rare glimmer of hope in an otherwise bleak climate landscape,' he wrote in an email response. It also shows that a country can cut emissions while still growing economically, he said. But Li cautioned that China's heavy reliance on coal remains a serious threat to progress on climate and said the economy needs to shift to less resource-intensive sectors. 'There's still a long road ahead,' he said. One solar farm can power 5 million households A seemingly endless expanse of solar panels stretches toward the horizon on the Tibetan plateau. White two-story buildings rise above them at regular intervals. Sheep graze on the scrubby vegetation that grows under them. Solar panels have been installed on about two-thirds of the land. When completed, it will have more than 7 million panels and be capable of generating enough power for 5 million households. Like many of China's solar and wind farms, it was built in the relatively sparsely populated west. A major challenge is getting electricity to the population centers and factories in China's east. 'The distribution of green energy resources is perfectly misaligned with the current industrial distribution of our country,' Zhang Jinming, the vice governor of Qinghai province, told journalists on a government-organized tour. Part of the solution is building transmission lines traversing the country. One connects Qinghai to Henan province. Two more are planned, including one to Guangdong province in the southeast, almost at the opposite corner of the country. Making full use of the power is hindered by the relatively inflexible way that China's electricity grid is managed, tailored to the steady output of coal plants rather than more variable and less predictable wind and solar, Myllyvirta said. 'This is an issue that the policymakers have recognized and are trying to manage, but it does require big changes to the way coal-fired power plants operate and big changes to the way the transmission network operates,' he said. 'So it's no small task.' ___ Moritsugu reported from Beijing. Associated Press video producer Wayne Zhang contributed. ___ The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at Ken Moritsugu And Ng Han Guan, The Associated Press
Yahoo
43 minutes ago
- Yahoo
Basilea Pharmaceutica Ltd (BPMUF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Global In-Market Sales Increase: Procemba sales increased by 24.8% for the 12-month period ending March 2025. Royalty Income Growth: 21.7% year-on-year increase in royalty income. Operating Result: Positive operating result of CHF 24 million for the first six months of 2025. Additional Funding: Secured $39 million in non-dilutive funding from BAA. Revenue: Total revenue of CHF 104 million, a 36% increase compared to the first half of 2024. Operating Expenses: CHF 55.7 million, mainly due to costs associated with the ongoing phase 3 program. Net Profit: CHF 15.8 million, compared to CHF 20.7 million in the first half of 2024. Net Cash Position: Positive net cash position of CHF 50.7 million as of June 30, 2025. Operating Cash Flow: Positive cash flow of CHF 23.1 million from operating activities. Debt Reduction: Reduced total debt by CHF 138.3 million from 2022 through June 30, 2025. Full Year 2025 Guidance: Total revenue expected to increase by about 8% to CHF 225 million. R&D Expenses: Projected to rise to CHF 105 million for 2025. Operating Profit Guidance: Expected operating profit of approximately CHF 50 million for 2025. Warning! GuruFocus has detected 5 Warning Signs with BPMUF. Is BPMUF fairly valued? Test your thesis with our free DCF calculator. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Basilea Pharmaceutica Ltd (BPMUF) reported a strong financial performance for the first half of 2025, with a positive operating result of CHF 24 million. The company's leading commercial product, Procemba, saw a 24.8% increase in global in-market sales, contributing to a 21.7% year-on-year increase in royalty income. Basilea secured an additional $39 million in non-dilutive funding from BAA to support the development of its antifungal candidates. The company successfully launched its antibiotic Zayra in the US through a partnership with Innoviva Specialty Therapeutics. Basilea expanded its portfolio by in-licensing ceftibutin deaborbactam, a phase 3 ready novel oral antibiotic for complicated urinary tract infections. Negative Points The net profit for the first half of 2025 decreased to CHF 15.8 million from CHF 20.7 million in the first half of 2024, due to a one-time income tax benefit in the previous year. The company anticipates a 17% reduction in product revenue to about CHF 48 million year-on-year due to a decrease in product supply to Pfizer. R&D expenses are projected to rise to CHF 105 million, driven by the in-licensing transaction and associated costs. The phase 3 program for the newly in-licensed antibiotic is expected to start in approximately 18 months, which may delay potential revenue contributions. Currency fluctuations, particularly the devaluation of the US dollar against the Swiss franc, impacted financial results. Q & A Highlights Q: Why is there an 18-month delay before starting the phase 3 trial for the newly in-licensed antibiotic? Does this relate to securing additional funding? A: David Veitch, CEO, clarified that the delay is not due to funding issues. The 18-month period is necessary for regulatory interactions with health authorities and operational setup. Marc Engelhardt, CMO, added that the studies require a large patient supply, which takes time to prepare. Q: How does the expanded access program for fosmanogepix impact regulatory approval, given the large number of patients involved? A: Marc Engelhardt, CMO, explained that the data from the expanded access program could serve as confirmatory evidence in an NDA filing, provided it meets FDA guidelines for completeness and context. Q: How does the new oral antibiotic fit into the treatment landscape for complicated UTIs, which is dominated by IV treatments? A: Marc Engelhardt, CMO, stated that the oral antibiotic will serve both as an initial empirical therapy and a step-down treatment from IV antibiotics, offering flexibility in hospital and outpatient settings. Q: Why is there expected softness in product revenues in the second half of the year? A: Adesh Kaul, CFO, explained that the fluctuation is due to product delivery schedules and initial supplies related to the US launch and other markets, rather than any underlying weakness. Q: What factors could accelerate enrollment in the fosmanogepix phase 3 program? A: Marc Engelhardt, CMO, mentioned that geographic analysis and increased sponsor engagement at underperforming sites could enhance enrollment rates. Q: Can you provide details on the sales and marketing infrastructure for Zevtera's US rollout? A: David Veitch, CEO, highlighted that Innoviva Specialty Therapeutics has extensive experience in launching antibiotics, with a comprehensive US coverage including sales, medical affairs, and access teams. Q: How does the oral antibiotic compare to GSK's oral carbapenem in clinical development for complicated UTIs? A: Marc Engelhardt, CMO, noted that while there are similarities in trial design, the new antibiotic offers advantages in spectrum and dosing frequency, potentially capturing significant market share. Q: How is Crescemba performing in the APAC region, and how will it mitigate the impact of the 2027 loss of exclusivity? A: Adesh Kaul, CFO, reported strong growth in APAC, particularly in Japan, where exclusivity extends beyond 2027, contributing to sustained revenue despite upcoming patent expirations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
